Robert Burns

Work

Analyst Robert Burns works at HCWAINWRIGHT and is focused on the Healthcare sector with 217 price targets and ratings documented since 2019 spanning on 25 stocks. Analyst's average stock valuation to be materialised ratio is 22.66% with an average time for price targets to be met of 50.59 days.

Most recent stock forecast was given on FATE, Fate Therapeutics, Inc at 24-Jan-2023.

Robert Burns best performing recommendations are on ZYME (ZYMEWORKS INC).
The best stock recommendation documented was for ZYME (ZYMEWORKS INC) at 1/4/2023. The price target of $8 was fulfilled within 1 day with a profit of $0.33 (4.3%) receiving and performance score of 43.02.

Average potential price target upside

AADI BNTX CRBU CTMX FATE IGMS MGNX NRIX NUVB ORIC RLAY RPTX RVMD ADCT IKNA KRON NCNA PRTG TCRR TPTX ZYME SWTX NLTX PRLD YMAB

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

30

$17.13 (133.10%)

50

8 months 17 days ago

0/4 (0%)

$20.92 (103.21%)

Buy

48

$35.13 (272.96%)

49

9 months 18 days ago

0/4 (0%)

$27.01 (133.48%)

Buy

45

$31.97 (245.36%)

1 years 11 days ago

0/1 (0%)

$23.08 (105.29%)

Show more analysts
AADI BNTX CRBU CTMX FATE IGMS MGNX NRIX NUVB ORIC RLAY RPTX RVMD ADCT IKNA KRON NCNA PRTG TCRR TPTX ZYME SWTX NLTX PRLD YMAB